Relmada Therapeutics Inc (RLMD)
3.35
-0.14
(-4.01%)
USD |
NASDAQ |
May 17, 16:00
3.35
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics Research and Development Expense (Quarterly): 13.31M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 13.31M |
| December 31, 2023 | 14.75M |
| September 30, 2023 | 10.45M |
| June 30, 2023 | 13.74M |
| March 31, 2023 | 15.86M |
| December 31, 2022 | 26.87M |
| September 30, 2022 | 30.53M |
| June 30, 2022 | 30.91M |
| March 31, 2022 | 25.01M |
| December 31, 2021 | 25.27M |
| September 30, 2021 | 33.99M |
| June 30, 2021 | 17.33M |
| March 31, 2021 | 14.02M |
| December 31, 2020 | 14.90M |
| September 30, 2020 | 11.24M |
| June 30, 2020 | 5.324M |
| March 31, 2020 | 4.508M |
| September 30, 2019 | 1.887M |
| June 30, 2019 | 3.070M |
| Date | Value |
|---|---|
| March 31, 2019 | 1.276M |
| December 31, 2018 | 1.257M |
| September 30, 2018 | 1.422M |
| June 30, 2018 | 0.9593M |
| March 31, 2018 | 1.667M |
| December 31, 2017 | 0.1507M |
| September 30, 2017 | 0.1658M |
| June 30, 2017 | 0.1845M |
| March 31, 2017 | 0.4907M |
| December 31, 2016 | 0.2541M |
| September 30, 2016 | 0.3642M |
| June 30, 2016 | 0.6137M |
| March 31, 2016 | 0.6091M |
| December 31, 2015 | 2.118M |
| September 30, 2015 | 2.866M |
| June 30, 2015 | 2.865M |
| March 31, 2015 | 2.275M |
| December 31, 2014 | 2.092M |
| September 30, 2014 | 0.719M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.887M
Minimum
Sep 2019
33.99M
Maximum
Sep 2021
16.47M
Average
14.75M
Median
Dec 2023
Research and Development Expense (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | 3.518M |
| Lifecore Biomedical Inc | 2.116M |
| Harrow Inc | 2.149M |
| Corvus Pharmaceuticals Inc | 4.075M |
| Aquestive Therapeutics Inc | 5.932M |